NVIVQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVIVQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. InVivo Therapeutics Holdings's shares outstanding for the quarter that ended in Sep. 2023 was 3.11 Mil.
InVivo Therapeutics Holdings's quarterly shares outstanding stayed the same from Jun. 2023 (3.11 Mil) to Sep. 2023 (3.11 Mil).
InVivo Therapeutics Holdings's annual shares outstanding increased from Dec. 2021 (1.37 Mil) to Dec. 2022 (2.43 Mil). It means InVivo Therapeutics Holdings issued new shares from Dec. 2021 to Dec. 2022 .
The historical data trend for InVivo Therapeutics Holdings's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InVivo Therapeutics Holdings Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 0.01 | 0.02 | 0.95 | 1.37 | 2.43 |
InVivo Therapeutics Holdings Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 1.39 | 2.43 | 3.11 | 3.11 | 3.11 |
For the Biotechnology subindustry, InVivo Therapeutics Holdings's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where InVivo Therapeutics Holdings's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
InVivo Therapeutics Holdings (OTCPK:NVIVQ) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Brice Foose | 10 percent owner | 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367 |
Daniel R Marshak | director | C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073 |
Christina Morrison | director | ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107 |
Richard M. Toselli | director, officer: CEO and CMO | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Richard Christopher | officer: Chief Financial Officer | C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623 |
C Ann Merrifield | director | |
Bob Rosenthal | director | 20 NEWBURY ST, BOSTON MA 02116 |
Heather Hamel | officer: Chief Legal Officer and GC | ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139 |
Jeffrey Modestino | officer: See Remarks | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139 |
Christopher Mcnulty | officer: Chief Financial Officer | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Melanie Golarz | officer: Interim CFO | C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Jeffrey S. Hatfield | director | 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Pamela J Stahl | officer: Chief Commercial Officer | ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139 |
Richard John Roberts | director | ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Masuoka K. Lorianne | officer: Chief Medical Officer | C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070 |
From GuruFocus
By Business Wire Business Wire • 01-06-2022
By Business Wire Business Wire • 10-27-2020
By Business Wire Business Wire • 09-08-2021
By Business Wire Business Wire • 07-06-2021
By Business Wire Business Wire • 09-09-2021
By GuruFocus Research • 02-08-2024
By Business Wire Business Wire • 07-13-2021
By Business Wire Business Wire • 02-16-2021
By Business Wire Business Wire • 04-14-2022
By Business Wire Business Wire • 06-02-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.